Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Awesome. Waited to get back in and with a $2 discount.
Cheers and look fed to the next leg up!
Absolutely agree
Couldn't ask for another opportunity to get back into this stock!
Gl mate
THLD:
ENJOY THE RIDE!
IT WAS WELL EARNED!
The company announced in February 2012 that the study met its primary endpoint demonstrating a statistically significant 63% improvement (p=0.005) in progression free survival (PFS) for patients treated with TH-302 and gemcitabine versus gemcitabine alone. This represented a 2-month increase in PFS for patients treated with TH-302.
GL
ENJOY THE RIDE!
IT WAS WELL EARNED!
The company announced in February 2012 that the study met its primary endpoint demonstrating a statistically significant 63% improvement (p=0.005) in progression free survival (PFS) for patients treated with TH-302 and gemcitabine versus gemcitabine alone. This represented a 2-month increase in PFS for patients treated with TH-302.
GL
Nicely said....
Gl
Agree, I underestimated the company and congrats too those that stayed the course.
Cheers to all!
Gl
The question is if the Carlyle group is more inshore interest or value. As that will be determined by the Chinese market and equity holdings at the time of transaction
Either way they will make money on the company via investment or liquidation.
Gl and enjoy the ride!
Cheera
Many shareholders investors nd traders have come a long way with this investment.
What do we do know.....hehe
Gl all!
Strong and steady day
Worth a hold
Gl
Bought heavy under $14 for the dividend and long term value.
Great investment and $20 should be a breeze
Gl
Great article, and this what they do and well
Gl
This company is exhibiting a beautiful chart.
Should be interesting time ahead of the upcoming 20's
Gl to all!
It was a probably introduction to the financial to say
Hi. I'm dr yu.......:)
But the reason why many of us own shares to companies like this and berkshires A. Is the brand an the reputation of success.
Gl
Agree with the symbolism
Of your comment, but don't let the love kick you in the a@@ on the way out.
Check out the article that should temper your love, but not affect your pocket book:
The private equity powerhouse’s proposed IPO is an affront on shareholder rights and any sense of corporate accountability.
By Eleanor Bloxham, CEO of The Value Alliance and Corporate Governance Alliance
Carlyle Group founders (left to right) William Conway, Daniel D'Aniello, and David Rubenstein
FORTUNE — We’ve seen companies like News Corp (NWS), Blackstone (BX), and LinkedIn (LNKD) chip away at shareholder rights by limiting the voting rights of shareholders. Now Carlyle is adding insult to injury.
In its recent proposed initial public offering (IPO), Carlyle will have no requirements for an independent board, virtually no voting rights for owners, and no ability for owners to sue. As an added bonus, owners will be paying its tax liabilities without any surety that they will receive cash distributions sufficient to cover those costs.
So, what would happen if every company did a Carlyle-style IPO? The private equity firm’s IPO proposal, which is brought to you by the clever folks at J.P. Morgan (JPM), Citigroup (C), and Credit Suisse (CS), with some help from law firms Simpson Thacher and Skadden Arps begs us to ask the question.
For example, on the tax front, what if all large companies were to adopt Carlyle’s approach where the owners (called unit-holders, which is analogous to shareholders) pay the corporation’s taxes? What impact would eliminating corporate income taxes (which is required of C-corporations) have on our economy and budget deficit?
It’s not an unreasonable question, Bob Monks, founder of LENS Investment Management, told me. “Companies are already moving offshore to avoid taxes, fiduciary duties, and regulatory responsibilities. It is astounding how much business is already transacted in offshore tax-havens,” he says.
According to Carlyle documents filed with the SEC, the proposed IPO “involves complex provisions of U.S. federal income tax for which no clear precedent or authority may be available.” Owners will be subject to that risk. Congress could act to preclude the Carlyle tax structure, but it has not passed anything so far, the documents state.
In addition to the tax risk, with no real shareholder rights in place, there is no accountability by Carlyle to those who buy their units/shares. What if every corporation adopted such a stance?
Money managers (who are hired to invest the monies of institutions or mutual funds, pension plans, or individuals’ savings or retirement accounts) at least have fiduciary obligations to their clients and should not be able to invest in such draconian offerings as a matter of prudence.
“I’d go one step further,” Monks told me. “They are barred from investing in offerings like Carlyle’s as a matter of both law and ethics.”
Former SEC chair and current Carlyle senior advisor Arthur Levitt recently told Bloomberg that taking away investors’ right to sue “could diminish the public appetite for Carlyle stock” and “companies that consider going down this road take a perceptual risk which, in terms of an IPO, is probably not a risk worth taking.”
But will money managers follow their obligations and avoid this offering? And if they don’t, will regulators enforce the fiduciary obligations money managers owe their clients?
As the IPO is currently designed, the SEC could block the IPO outright. But Lynn Turner, former chief accountant at the SEC, told me “Given the level of regulatory capture and close ties to the securities industry at the current SEC, it is quite possible, if not likely, the SEC will allow the Carlyle IPO to move forward, to disastrous effect.”
Perhaps Carlyle, which did not respond to a request for comment, would back down if money managers refused to invest. That would be a welcome repetition of history.
Former Goldman Sachs (GS) chairman John Whitehead spoke to me several years ago about how he fought offerings that diminished shareholder rights. “When I was chairman … there began to grow up a practice of managements deciding to sell non-voting stock to the public…. And I immediately thought that that was a bad idea. That people’s capitalism, the system that we have, depends on the age-old system of one-share-one-vote…. So Goldman Sachs decided that it would not underwrite non-voting stock, and that was a surprise because we lost some business when companies came to us and asked us.”
Once Goldman stopped underwriting non-voting stock, others began to reconsider. “And gradually, it fell out of practice,” Whitehead said. “And gradually, companies that had those kinds of shares eliminated their non-voting shares and then replaced them with full voting rights.”
Giving shareholders a say is “a self-cleansing process” and encourages companies to institute good practices, he said.
The health of capitalism itself depends on basic shareholder rights and money managers should be willing to fight for those rights. But will they? Will they remember who their customers are?
If Carlyle’s IPO moves forward with any measure of success, other companies may indeed follow suit. Corporate history is replete with examples of financial services firms creating major crises (including our most recent crisis) by acting like lemmings. Former Citi CEO Sandy Weill‘s Travelers-Citi merger pushed legislators to repeal the Glass-Steagall Act. Many large banks jumped on that bandwagon and began to sell financial instruments even they did not understand. We know the result for taxpayers and the economy.
Carlyle’s IPO raises a fundamental question about our future: we know capitalism was never perfect — but are we really ready for the end of capitalism as we once knew it, when it worked?
Eleanor Bloxham is CEO of The Value Alliance and Corporate Governance Alliance (http://thevaluealliance.com), a board advisory firm.
Pretty good volume of 30 minutes of trading.
For what it's worth anticipation has value
Gl
anything under $15 is a deal with the current quarterly dividend pay outs.
the future is bright.
accumulate while you can.
gl
i agree, i'm assuming profit taking.
as i'm still skeptical of this bullish run (but what the hell do i know, as i said that when stx was $26...lol)
gl
:)
Next stop $28
Slow and steady
Gl
In due time, this not for the quick flip
Gl
CNBC going bullish for "hardware"
For the last few minutes
Giddie-up!
Gl
Well said
Cheers!
Hopefully soon!
Gl
i second that!
gl
Keep an eye on "work day" iPo
Could be a steal with early entry
Along with yelp, and Carlyle group, is one of my favorites.
Recent partnership with google can really generate revenues to compete the giants like oracle.
Below is a Forbes article:
Workday, which provides software for human resources, payroll and financial management, has filed for an initial public stock offering of up to $400 million. The company was founded in 2005 by PeopleSoft founder Dave Duffield and venture capitalist Aneel Bhusri.
Revenue at the compnay increased from $25.2 million in 2009 to $134.4 million for the year ending January 31. Losses rosefrom $49.9 million to $79.6 million over the same period. As of July 31, 2012, Workday had an accumulated deficit of $329.5 million.
The IPO could be the biggest to hit the market since Facebook (FB) earlier this year.
No escape for the POWs!
;)
Gl!
Killer volume!
Gl
NeurogesX' NGX-1998 Well-Tolerated Treatment Demonstrated Clear Dose-Response in Patients
gl
The Carlyle Group and DuPont today announced that they have signed a definitive agreement whereby Carlyle will purchase DuPont Performance Coatings (DPC) for $4.9 billion in cash
gl
Dr. Singh Interview Update 1 comment
Aug 30, 2012 3:38 AM | about stocks: IMUC
On Tuesday, I had a great conversation with Dr Singh over his departure from ImmunoCellular Therapeutics (IMUC) and his perspectives on ICT-107. This was one of the most honest and upfront interviews I have done. However, Dr Singh wanted to make sure his counsel approved the publication before it got submitted and at this time has not reviewed or released the transcript.
Unfortunately the legal advice to him was to not make this interview public for the time being. This is unfortunate as he was candid and honest in his answers on every question I had asked without dodging anything. To respect his counsel's advice, Dr Singh has requested not to publish this interview now but he would like this to be published at sometime down the road.
However, I will inform everyone that his departure had nothing to do with the potential of ICT-107 on which he was bullish in his interview as one of the best immunotherapy products in development or the other candidates they have been preparing for trials. In fact, he was very positive with his outlook on IMUC's products and also his professional endeavors. His departure was really due to his differences with the Board on operational and strategic issues and not related to allegations regarding clinical data and misrepresentation, as he put any unethical concerns to rest.
I understand that for some of you this will be unacceptable. I can assure you that the interview consists of the information that I have provided above, as the only goal was to determine why he resigned
from IMUC. I believe it is safe to say that no one wanted answers more than myself, as I have probed, emailed, and attempted to communicate on a daily basis since his departure.
After I had received the email from Dr. Singh regarding the interview I made the mistake of announcing the interview publicly, and also announced my goal to publish on Thursday. However, this was a result
of pure excitement on my behalf, and I should've made a more professional assessment of the situation surrounding this news before providing a target date.
The interview itself was very last minute, and the issues with publication are a result of my own lack of preparation. The reason is because of my process when conducting interviews, and some may
understand and others will become frustrated. You see when I interview any executive or a CEO, and publish it as a transcript, I ensure that either A) I obtain a release from the interviewee stating that all statements and use of words are correct or B) allow someone at the company, or the person, to read the transcript and send an email in response saying that the words are correct and were said during the interview (possibly why he agreed to the interview). And due to the nature of the topic it is absolutely crucial that all words, phrases, and statements are correct and are acknowledged by the person as being his own words.
You might be thinking, "that's what recorders are for" or "don't you have emails?" The simple answer is that because of the interview's terminology, situation, length, and concerns over accuracy on my part
it was crucial for me that Dr. Singh have the opportunity to review and ensure that all information was correct, especially considering the rate at which the interview occurred and the fact that every possible
situation that could go wrong went wrong. Therefore, it is important that everything is verified so that readers have the truth and there are no disputes, and at this point I have not received an "ok" from Dr.
Singh. Even though Dr Singh was very candid and upfront in his answers, he wanted to make sure his legal counsel approved of this interview. Unfortunately, lawyers being a conservative bunch didn't think this should be published until a certain time period in the future.
In closing I would like to conclude and reiterate that I will at some point in the near future be publishing this transcript. There are several great questions that were sent from readers that I did not receive until
after the interview was complete, in which he will respond and I will include in the transcript. It is not my goal to keep anything from my readers, which is why I summed up the main points of the interview
in the first paragraph. His resignation was a decision made by him, and he was not forced out, and if anything it was due to differences with the Board on strategic and operational issues. He did say on
several occasions that the decision was "agonizing" and described the company as the "best team in immunotherapy drug development". It had nothing to do with any clinical data or expected results of
ICT-107 as he did say that he believed ICT-107 to be the best designed immunotherapy product today. He also emphasized that everything presented or put on the press release so far in terms of the clinical data has been accurate and there is no validity in any misrepresentations been made in the past.
I know that what I have provided does not answer all questions, and for that I apologize. The wise decision would've been not to announce that I was speaking with him. However, I was excited, and had worked very hard to reach out, and although it may be a little longer before I can publish the interview in its entirety I do hope that this at least provides some answer to his reasons for stepping down, which was the goal of us speaking.
Disclosure: I am long IMUC.
Additional disclosure: The information in this article is for educational purposes only and should not be used in determining any investment decisions
Stocks: IMUC
Gl mate, I will let the market dictate the news.
Take care
Interesting trading day small hits are consistently pushing the ask
No complaints here
Lucky, your one persistent chap
All about results, tick tock tick tock tick tock tick.......
Shares on the market order, let public sentiment control the pps
Cheers!
The attached Press Release was issued on August 29, 2012
Medgenics' Novel Tissue Implant Approved for Two Hepatitis C Clinical Trials in Israel
First in man clinical trials of INFRADURE Biopumps for the continuous production of interferon alpha from patient's own tissue
Gl
Lol, probably not that low but sure people are hoping
Play the stock, not the audacity of hope.....:)
Gl
Good opportunity for re entry for traders and investors.
Let's see how it bounces
Gl
Pretty ugly
Gl
So lucky, when do you think this will happen
Pretty hot and cold.....:)
Gl
consolidation, and well deserved breather.
gl